RU2718780C9 - Способы лечения рака легкого - Google Patents

Способы лечения рака легкого Download PDF

Info

Publication number
RU2718780C9
RU2718780C9 RU2017136863A RU2017136863A RU2718780C9 RU 2718780 C9 RU2718780 C9 RU 2718780C9 RU 2017136863 A RU2017136863 A RU 2017136863A RU 2017136863 A RU2017136863 A RU 2017136863A RU 2718780 C9 RU2718780 C9 RU 2718780C9
Authority
RU
Russia
Prior art keywords
fra
seq
antibody
expression
patient
Prior art date
Application number
RU2017136863A
Other languages
English (en)
Russian (ru)
Other versions
RU2017136863A3 (enExample
RU2017136863A (ru
RU2718780C2 (ru
Inventor
Даниель Джон О'ШАННЕССИ
Original Assignee
Эйсай Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйсай Инк. filed Critical Эйсай Инк.
Publication of RU2017136863A publication Critical patent/RU2017136863A/ru
Publication of RU2017136863A3 publication Critical patent/RU2017136863A3/ru
Application granted granted Critical
Publication of RU2718780C2 publication Critical patent/RU2718780C2/ru
Publication of RU2718780C9 publication Critical patent/RU2718780C9/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RU2017136863A 2015-04-17 2016-04-14 Способы лечения рака легкого RU2718780C9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149184P 2015-04-17 2015-04-17
US62/149,184 2015-04-17
PCT/US2016/027497 WO2016168440A1 (en) 2015-04-17 2016-04-14 Methods for treating lung cancer

Publications (4)

Publication Number Publication Date
RU2017136863A RU2017136863A (ru) 2019-05-17
RU2017136863A3 RU2017136863A3 (enExample) 2019-08-21
RU2718780C2 RU2718780C2 (ru) 2020-04-14
RU2718780C9 true RU2718780C9 (ru) 2020-07-08

Family

ID=55809240

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017136863A RU2718780C9 (ru) 2015-04-17 2016-04-14 Способы лечения рака легкого

Country Status (13)

Country Link
US (1) US20180125970A1 (enExample)
EP (1) EP3283886B1 (enExample)
JP (1) JP2018516244A (enExample)
KR (1) KR20170137848A (enExample)
CN (1) CN107624071A (enExample)
AU (1) AU2016248222A1 (enExample)
BR (1) BR112017022320A2 (enExample)
CA (1) CA2983126A1 (enExample)
IL (1) IL255079A0 (enExample)
MX (1) MX2017013390A (enExample)
RU (1) RU2718780C9 (enExample)
SG (1) SG11201708546UA (enExample)
WO (1) WO2016168440A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
US20170247449A1 (en) * 2014-06-06 2017-08-31 Kyowa Hakko Kirin Co., Ltd Therapeutic method and medicament for cancer patients by folr1-targeting drug and an antagonist for folic acid metabolism
US10822410B2 (en) 2016-11-23 2020-11-03 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
EP3765521A4 (en) 2018-03-13 2022-03-23 Phanes Therapeutics, Inc. ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF
JP7379390B2 (ja) * 2018-06-18 2023-11-14 メドイミューン・リミテッド 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ
CN110221052B (zh) * 2019-06-17 2022-09-23 昆山德诺瑞尔生物科技有限公司 Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用
EP4490517A1 (en) * 2022-03-11 2025-01-15 Astrazeneca AB A scoring method for an anti-fr alpha antibody-drug conjugate therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2529797C2 (ru) * 2007-09-18 2014-09-27 Кэнсер Рисёч Текнолоджи Лтд Раковый маркер и терапевтическая мишень

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
SG189957A1 (en) 2010-11-05 2013-06-28 Morphotek Inc Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers
CN107011439B (zh) * 2011-07-15 2020-11-10 卫材R&D管理有限公司 抗叶酸受体α抗体及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2529797C2 (ru) * 2007-09-18 2014-09-27 Кэнсер Рисёч Текнолоджи Лтд Раковый маркер и терапевтическая мишень

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
THOMAS A. et al. " Farletuzumab in lung cancer". Lung Cancer 2013 April;80(1):15-18, doi: 10/1016/j.1ungcan.2012.12.021. O'SHANNESSY DJ. et al. "Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance". Oncotarget 2012 Apr;3(4):414-25, , найдено 19.08.2019 из PubMed PMID:22547449. O'SHANNESSY DJ. et al. *
THOMAS A. et al. " Farletuzumab in lung cancer". Lung Cancer 2013 April;80(1):15-18, doi: 10/1016/j.1ungcan.2012.12.021. O'SHANNESSY DJ. et al. "Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance". Oncotarget 2012 Apr;3(4):414-25, реферат, найдено 19.08.2019 из PubMed PMID:22547449. O'SHANNESSY DJ. et al. "Characterization of the Human Folate Receptor Alpha Via Novel Antibody-Based Probes". Oncotarget 2011;2:1227-1243. *

Also Published As

Publication number Publication date
US20180125970A1 (en) 2018-05-10
RU2017136863A3 (enExample) 2019-08-21
IL255079A0 (en) 2017-12-31
JP2018516244A (ja) 2018-06-21
WO2016168440A1 (en) 2016-10-20
EP3283886B1 (en) 2020-01-15
CA2983126A1 (en) 2016-10-20
AU2016248222A1 (en) 2017-11-09
RU2017136863A (ru) 2019-05-17
RU2718780C2 (ru) 2020-04-14
MX2017013390A (es) 2018-06-13
CN107624071A (zh) 2018-01-23
SG11201708546UA (en) 2017-11-29
EP3283886A1 (en) 2018-02-21
BR112017022320A2 (en) 2018-07-24
KR20170137848A (ko) 2017-12-13

Similar Documents

Publication Publication Date Title
RU2718780C2 (ru) Способы лечения рака легкого
US8470542B2 (en) Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
US20190202930A1 (en) Methods for treatment of ovarian cancer
US10221240B2 (en) Methods for treatment of gastric cancer
US20190154694A1 (en) Detection and treatment of cancer
JP6468838B2 (ja) 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法
WO2022154037A1 (ja) がんの予後バイオマーカー
US12455289B2 (en) Monoclonal antibodies against loricrin
WO2019064073A1 (en) USE OF CA125 FOR PREDICTING ANTI-MESOTHELIC TREATMENT OF MESOTHELIOMES
US20250189528A1 (en) Biomarkers for disease progression and/or recurrence in squamous cell carcinoma
CN107850599A (zh) Wbp2与her2作为共预后因子对患者分层以进行治疗
CN110546510A (zh) 预后方法和在所述方法中有用的试剂盒
NZ711375A (en) Methods for increasing efficacy of folr1 cancer therapy

Legal Events

Date Code Title Description
TH4A Reissue of patent specification
MM4A The patent is invalid due to non-payment of fees

Effective date: 20210415